Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug could help eradicate hidden leukemia cells

NCT ID NCT02888964

Disease control Sponsor: Versailles Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding pioglitazone (a diabetes drug) to the standard leukemia medication imatinib can eliminate remaining cancer cells in people with chronic-phase chronic myeloid leukemia (CML). Participants must have been on imatinib for at least two years and have a stable low level of leukemia cells. The goal is to see if the combination can achieve a complete molecular response, meaning no detectable leukemia cells, within 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pioglitazone (Actos) added to imatinib mesylate (Gleevec)
What this could lead to
If successful, this combination could help more CML patients achieve undetectable levels of leukemia cells, potentially allowing some to stop treatment without relapse.
What could go wrong
This is a small early-phase trial with only 27 participants, so results may not apply broadly. Pioglitazone has known side effects including fluid retention and risk of bladder cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

27 people

The number who actually took part.

Start date

Dec 2009

Finished

Feb 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient aged 18y or more 2. Signed informed consent 3. Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL transcript positivity 4. Treatment with imatinib for more than 2 years 5. No dose modification of imatinib within the last 3 months 6. Complete cytogenetic response on the last cytogenetic analysis within the last 12 months 7. Major molecular remission without complete molecular remission 8. ECOG grade 0 to 2 9. SGOT et SGPT ≤ 2.5 N 10. Bilirubin in serum ≤ 1.5 N 11. Women of childbearing potential (WOCBP) must be using an adequate method of contraception Exclusion Criteria: 1. Participation in another clinical trial with any investigative drug within 30 days prior to study enrollment 2. Prior history of hematopoietic stem cell transplantation (autologous or allogenic) 3. Patient requiring anti-diabetic medication 4. Cardiovascular disease: * Stage I to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure * Myocardial infarction within the previous 6 months * Symptomatic cardiac arrhythmia requiring treatment 5. Grade III or IV fluid retention 6. Known osteoporosis with therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leukemia, myeloid, chronic-phase are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myeloid, Chronic-Phase

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leukemia, myeloid, chronic-phase

Contacts and locations

Locations

  • CH Versailles

    Le Chesnay, France

  • CHR Annecy

    Annecy, France

  • CHU Lille

    Lille, France

  • CHU Poitiers

    Poitiers, France

  • CHU Purpan

    Toulouse, France

  • CHU archet 1

    Nice, France

  • IPC

    Marseille, France

  • Institut Bergonié

    Bordeaux, France

  • St Louis

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.